Main image of with a Heart surrounded by an EMBLEM and a EMPOWER devices

gdffdrdrtdrtst

EMBLEM™ S-ICD Clinical Performance Proven Over Decades

Proven Protection. Personalised Care.

Image of an EMPOWER device in dark background

Key Studies & Trial Outcomes

MODULAR ATP Study

The EMPOWER™ Leadless Pacemaker (LP) demonstrated a 97.5% complication-free rate when integrated with the Subcutaneous Implantable Cardioverter Defibrillator (S-ICD).1 Read More

PRAETORIAN Trial

The S-ICD was associated with a lower risk of major and lead-related complications compared with the transvenous ICD (TV-ICD).2,3 Read More

ATLAS Trial

The S-ICD demonstrated a 92% reduction in serious lead-related complications compared with single-chamber TV-ICDs from any manufacturer.4 Read More

HONEST Cohort Study

Routine defibrillation testing can be safely omitted in most S-ICD implants, reinforcing the therapy’s proven safety, predictability, and simplicity in real-world practice.5 Read More

Clinical Proof Points

Icon: 150,000+ EMBLEM S-ICD implants

patients

implanted with the EMBLEM™ S-ICD worldwide.6

 

Icon: 92% fewer lead-related issues

reduction

in serious lead-related complications compared with TV-ICDs.4

Icon: Calendar showing 8.7 years of device longevity

years

device longevity for sustained protection.7

HONEST Cohort Study: Redefining the Role of Defibrillation Testing in S-ICD

The nationwide HONEST French Cohort (n=4,924) brings new clarity on defibrillation testing (DT) during S-ICD implantation.5

Published in JACC, the study shows that routine DT can be safely omitted for most patients, without increasing mortality or inappropriate shocks, reinforcing the predictability, safety, and simplicity of the S-ICD procedure.5

Read the HONEST Study Summary
Two healthcare professionals talking - Banner for the Clinical EVIDENCE Newsletter

Stay Informed with our Clinical EVIDENCE Newsletter

We aim to provide you with cutting-edge information that will keep you up to date on the latest clinical data and the most recent advancements in the field of heart failure management and sudden cardiac death prevention.

Learn more


References:

1.Knops RLM, Roberts PR, Roberts PR, et al. A Modular Communicative Leadless Pacing-Defibrillator System. N Engl J Med. 2024;391(15):1402–1412.

2.Knops RE, Olde Nordkamp LRA, Delnoy PHM, et al. Subcutaneous or Transvenous Defibrillator Therapy. N Engl J Med. 2020;383(6):526–536.

3.Nordkamp LO. Device-related complications in transvenous versus subcutaneous defibrillator therapy during long-term follow-up: The PRAETORIAN XL Trial. Circulation. 2025. doi: 10.1161/CIRCULATIONAHA.125.074576.

4.Healey JS, Krahn AD, Bashir J, et al. Perioperative safety and early patient and device outcomes among subcutaneous versus transvenous implantable cardioverter defibrillator implantations: a randomized, multicenter trial. Ann Intern Med. 2022;175(12):165–1665

5.Kerkouri F, Eschalier R, Fareh S, et al. Defibrillation Testing During Implantation of Subcutaneous Implantable Cardioverter Defibrillators. J Am Coll Cardiol. 2025 Jul 8;86(1):32-45. doi: 10.1016/j.jacc.2025.04.048.

6.Boston Scientific CRM Product Performance Report published December 4th, 2023. Data as of October 3rd, 2023.

7.Boston Scientific. EMBLEM™ S-ICD user manual. Available at: https://www.bostonscientific.com/content/dam/bostonscientific/Rhythm%20Management/portfolio-group/EMBLEM_SICD/Download_Center/359481-001%20EMBLEM%20S-ICD%20PTM_English.pdf. [Accessed September 2024].Boston Scientific. EMBLEM™ S-ICD User Manual. Available at: https://www.bostonscientific.com
 

ICD, implantable cardioverter defibrillator; LP, leadless Pacemaker; S-ICD, subcutaneous ICD; TV-ICD, transvenous ICD.


CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device. or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.